We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

96 hedge funds and large institutions have $161M invested in Lineage Cell Therapeutics in 2017 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 5

117% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 18

10% more capital invested

Capital invested by funds: $146M → $161M (+$15.1M)

4% more funds holding

Funds holding: 92 → 96 (+4)

3.43% more ownership

Funds ownership: 44.75% → 48.18% (+3.4%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

97% less call options, than puts

Call options by funds: $3K | Put options by funds: $103K

Holders
96
Holders Change
+4
Holders Change %
+4.35%
% of All Funds
2.39%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
39
Reduced
18
Closed
5
Calls
$3K
Puts
$103K
Net Calls
-$100K
Net Calls Change
-$81K

Top Buyers

1
BlackRock
BlackRock
New York
+$15.9M
2
BC
Broadwood Capital
New York
+$7.21M
3
PGP
Prescott General Partners
Florida
+$6.01M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.08M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.34M

Top Sellers

1
MHP
Manatuck Hill Partners
Connecticut
-$357K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$268K
3
Two Sigma Investments
Two Sigma Investments
New York
-$239K
4
Citigroup
Citigroup
New York
-$222K
5
Morgan Stanley
Morgan Stanley
New York
-$198K
Name Holding Trade Value Shares
Change 		Change in
Stake
VKH
26
Virtu KCG Holdings
New York
$283K +$223K +78,390 +508%
PNC Financial Services Group
27
PNC Financial Services Group
Pennsylvania
$278K – – –
Wells Fargo
28
Wells Fargo
California
$260K -$3.59K -1,265 -1%
WJA
29
Williams Jones & Associates
New York
$243K +$32.5K +11,430 +17%
New York State Common Retirement Fund
30
New York State Common Retirement Fund
New York
$240K +$71.4K +25,147 +46%
GPCM
31
Granite Point Capital Management
Massachusetts
$235K -$34.2K -12,058 -13%
CA
32
Corrado Advisors
New Jersey
$213K +$91.1K +32,090 +83%
Manulife (Manufacturers Life Insurance)
33
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$212K +$26.9K +9,484 +16%
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$210K +$13.7K +4,833 +7%
MLICM
35
Metropolitan Life Insurance Company (MetLife)
New York
$199K +$24.1K +8,471 +15%
NCCM
36
Nine Chapters Capital Management
New Jersey
$196K +$185K +65,037 New
AllianceBernstein
37
AllianceBernstein
Tennessee
$189K – – –
SFA
38
Sequoia Financial Advisors
Ohio
$169K – – –
CAM
39
ClariVest Asset Management
California
$169K +$159K +55,944 New
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$167K -$6.82K -2,401 -4%
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$159K -$268K -94,211 -64%
NFA
42
Nationwide Fund Advisors
Ohio
$154K +$3.05K +1,074 +2%
AIG
43
American International Group
New York
$137K +$9.86K +3,471 +8%
MC
44
Moors & Cabot
Massachusetts
$134K +$17.2K +6,058 +15%
HP
45
Hikari Power
Japan
$122K +$114K +40,318 New
IP
46
Intellectus Partners
California
$121K – – –
Deutsche Bank
47
Deutsche Bank
Germany
$115K -$23.4K -8,228 -17%
CD
48
Carl Domino
Florida
$114K – – –
GC
49
Guggenheim Capital
Illinois
$113K +$236 +83 +0.2%
RJA
50
Raymond James & Associates
Florida
$110K +$104K +36,507 New
1
2
3 4

LCTX Hedge Fund Activity: Q1 2017 in Review

96 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2017, worth a combined $161M — up 10% from $146M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new LCTX positions and 5 closed out — a net gain of 9 holders — while 39 added to existing stakes and 18 trimmed.

The largest buyer was BlackRock, adding an estimated $15.9M. The largest seller was Manatuck Hill Partners, cutting an estimated $357K.

  • 96 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2017, up from 92 in Q4 2016.
  • Funds reported $161M of Lineage Cell Therapeutics stock for Q1 2017, up 10% quarter-over-quarter.
  • 14 funds opened new Lineage Cell Therapeutics positions in Q1 2017 and 5 closed out, a net change of +9 holders.
  • The largest Lineage Cell Therapeutics buyer in Q1 2017 was BlackRock, an estimated $15.9M added.
  • The largest Lineage Cell Therapeutics seller in Q1 2017 was Manatuck Hill Partners, an estimated $357K sold.

Based on aggregated 13F filings for Q1 2017.